Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-02 · accession 0001968202-24-000054 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-06 | 2024-02-02 | REGN | STAHL NEIL | EVP Research, Development | F - Tax | $956.65 | -22.7K | 60.1K | -27% | -$21.73M |
| D | 2024-02-06 | 2024-02-02 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $399.66 | +30.8K | 82.8K | +59% | +$12.29M |
| D | 2024-02-06 | 2024-02-02 | REGN | STAHL NEIL | EVP Research, Development | M - OptEx | $0.00 | -30.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-02 | F | D | 22,713 | $956.65 | 60,056 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-02 | M | A | 30,750 | $399.66 | 82,769 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-02 | M | D | 30,750 | $0.00 | 0 | D | $399.66 · — to 2024-12-16 | 30,750 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |